目的 分析复方皂矾丸治疗FOLFOX4方案所致结直肠癌患者贫血的临床效果。方法 回顾性选择2022年1月—2024年6月中国科学技术大学附属第一医院收取的83例结直肠癌经FOLFOX4方案化疗后出现贫血的患者。按治疗贫血的方法不同将患者分为两组，对照组（n=41）应用重组人促红素注射液治疗；观察组（n=42）在对照组基础上采用复方皂矾丸治疗；对比两组近期效果、不良反应、贫血状况及骨髓造血功能等。结果 观察组近期贫血改善效果（85.71%）高于对照组（58.54%），治疗前两组患者中医主症、次症评分比较差异无统计学意义（P＞0.05），而在治疗后两组患者主症、次症评分均较本组治疗前显著降低（P＜0.05）；治疗后观察组主症、次症评分均显著低于对照组（P＜0.05）；治疗前两组各项客观指标[前白蛋白（PA）、白蛋白（ALB）、血红蛋白（Hb）、白细胞（WBC）、红细胞（RBC）、血小板计数（PLT）及CD3⁺、CD4⁺、CD4⁺/CD8⁺]比较差异无统计学意义（P＞0.05），而在治疗后两组各项客观指标均较本组治疗前显著降低（P＜0.05）；治疗后观察组各项指标均显著高于对照组（P＜0.05）。两组不良反应比较差异不显著（P＞0.05）。结论 复方皂矾丸可改善治疗FOLFOX4方案所致结直肠癌患者的贫血程度，提高其治疗效果，改善患者骨髓造血功能，值得临床推广应用。

Objective To analyze the clinical effect of Compound Zaofan Pill in the treatment of anemia in colorectal cancer patients caused by FOLFOX4 regimen. Methods A retrospective study was conducted on 83 patients with colorectal cancer who developed anemia after receiving FOLFOX4 chemotherapy at the First Affiliated Hospital of the University of Science and Technology of China from January 2022 to June 2024. Patients were divided into two groups according to different methods of treating anemia. The control group (n = 41) was treated with recombinant human erythropoietin injection, the observation group (n = 42) was treated with Compound Zaofan Pill on the basis of the control group. The recent effects, adverse reactions, anemia status, and bone marrow hematopoietic function was compared between two groups. Results The recent improvement effect of anemia in the observation group (85.71%) was higher than that in the control group (58.54%). There was no statistically significant difference in the scores of the main and secondary symptoms between the two groups of patients before treatment (P > 0.05), but after treatment, the scores of the main and secondary symptoms in both groups of patients were significantly lower than before treatment (P < 0.05). After treatment, the scores of the main and secondary symptoms in the observation group were significantly lower than those in the control group (P < 0.05). Before treatment, there was no statistically significant difference (P > 0.05) in the objective indicators of prealbumin (PA), albumin (ALB), hemoglobin (Hb), white blood cells (WBC), red blood cells (RBC), platelet count (PLT), and CD3⁺, CD4⁺, CD4⁺/CD8⁺ between the two groups. However, after treatment, all objective indicators in the two groups were significantly reduced compared to before treatment (P < 0.05). After treatment, all indicators in the observation group were significantly higher than those in the control group (P < 0.05). The difference in adverse reactions between the two groups was not significant (P > 0.05). Conclusion Compound Zaofan Pill can improve the anemia level in patients with colorectal cancer caused by FOLFOX4 regimen, enhance its therapeutic effect, improve the patient's bone marrow hematopoietic function, and is worthy of clinical promotion and application.

R979.1

安徽省2023年度中央财政中医药事业传承与发展专项资金项目（全国第七批全国名老中医专家学术经验继承项目专项基金340000201280030000414-医疗服务能力提升补助资金）